

Company Registration Number - 8013670

The Charity Registration Number is :- 1147506

Ocular Melanoma UK

Report and Accounts

31 March 2025

Ocular Melanoma UK

Report and accounts for the year ended 31 March 2025

Contents

	Page
Charity information	1
Trustees' Annual Report	1
Statement of directors' responsibilities	12
Independent Accountant's Report	14
<b>Funds Statements:-</b>	
Statement of Financial Activities	16
Statement of Financial Activities - Prior Year statement	17
Movements in funds	18
Income and Expenditure account	19
<b>Balance sheet</b>	20
<b>Notes to the accounts</b>	21

## **Ocular Melanoma UK**

Company Registration Number - 8013670

### **Trustees' Annual Report for the year ended 31 March 2025**

The Trustees present their Report and Accounts for the year ended 31 March 2025, which also comprises the Directors' Report required by the Companies Act 2006.

#### **Reference and administrative details**

##### ***The charity name.***

The legal name of the charity is:- Ocular Melanoma UK.

The charity is also known by its operating name, Ocular Melanoma UK, previously OcuMel UK (changed in August 2024).

##### ***The charity's areas operation and UK charitable registration.***

The charity is registered in England & Wales with the Charity Commission in England & Wales (CCEW) with charity number 1147506.

The charity does not operate in any overseas jurisdictions.

##### ***Legal structure of the charity***

The charity is constituted as a company limited by guarantee, registered under the Companies Acts.

The governing document of the charity is the Memorandum and Articles of Association establishing the company under company legislation.

The governing document is dated 26 March 2012

Updated Articles of Association and Special Resolution are dated 20th August 2024

There are no restrictions in the governing documents on the operation of the Charity or on its investment powers other than those imposed by Charity Law.

By operation of law all trustees are directors under the Companies Act 2006 and all directors are trustees under Charities legislation and have responsibilities, as such, under both company and charity legislation.

The trustees are all individuals.

##### **The principal operating address, telephone number, email and web addresses of the charity are:-**

139 Langley Road

Slough, Berkshire

UK, SL3 7DZ

Telephone 01753 357771

Email Address [info@omuk.org](mailto:info@omuk.org)

Web Address [www.omuk.org](http://www.omuk.org)

The registered office of the charity for Companies Act purposes is the same as the operating address shown above.

##### **The Trustees in office on the date the report was approved were:-**

Mr Neil Pearce

Mrs Alison Benjamin

Mrs Joanne Frye - Chair

Mr Colin White

Mrs Charlotte Edwards - Treasurer

## Ocular Melanoma UK

Company Registration Number - 8013670

### Trustees' Annual Report for the year ended 31 March 2025

The following persons served as Trustees during the year ended 31 March 2025 :-

The trustees who served as a trustee in the reporting period, and, if applicable, their dates of appointment or resignation during the year were:-

<i>Name</i>	<i>Appointed</i>	<i>Resigned/Retired</i>
Mr Neil Pearce		
Mrs Alison Benjamin		
Mrs Joanne Frye - Chair		
Mr Colin White		
Mrs Charlotte Edwards - Treasurer		
All the trustees are also members of the charity.		

### Objects and activities of the charity

#### *The purposes of the charity.*

Ocular Melanoma UK is the only UK charity solely dedicated to supporting people affected by ocular melanoma.

Established in 2009, we have been providing connection and compassionate support since 2011, so that anyone receiving this rare diagnosis has somewhere to turn for understanding, practical guidance, and a community that can make a difficult time feel less isolating.

During the 2024/25 financial year, we changed our name from OcuMel UK to Ocular Melanoma UK. The name change was formally registered on 20 August 2024 and was made to improve clarity, ensuring that patients, families, clinicians and stakeholders can more easily recognise the condition we support. This change supports our ongoing work to raise awareness, strengthen understanding, and connect more people affected by ocular melanoma with the right information and support.

We are determined to drive improvements so people can live well with ocular melanoma. This can be a devastating cancer, so we are working to ensure people have access to effective treatments and that clear pathways are in place, all while striving to provide specialist support to people who need it.

#### **What is ocular melanoma?**

Ocular melanoma is a cancer of the eye.

- We know approximately 750 people in the UK will hear they have ocular melanoma each year, and those people are likely to need support.

- We know we have existing patients in the UK living with ocular melanoma who may need support adjusting to life after their diagnosis.

- We also know that one in every two people will hear they need further treatment if the cancer spreads

- We know that no one should face this terrifying time alone.

Ocular melanoma includes two cancers, uveal and conjunctival melanoma. Uveal melanoma includes the iris, choroid or ciliary body. Both types of ocular melanoma can metastasise (spread) to other organs, with the liver typically involved in 90% of uveal melanoma cases.

If ocular melanoma spreads to another organ, it is currently incurable. Some treatments extend life expectancy and improve the quality of life for some patients, but patients can face difficulties accessing these treatments and clinical trials.

Ocular melanoma is usually discovered during a routine eye examination or when the patient experiences symptoms and goes to their GP or optometrist. If the optometrist or GP suspects cancer, they should urgently refer the patient to their local ophthalmology department. Should they agree with the concern, they will refer to one of four specialist centres: Glasgow, Liverpool, Sheffield or London.

## **Ocular Melanoma UK**

Company Registration Number - 8013670

### **Trustees' Annual Report for the year ended 31 March 2025**

#### **Why is Ocular Melanoma UK needed?**

People with ocular melanoma can feel very alone. The condition is so rare and the prognosis often so overwhelming that patients frequently report feeling isolated.

Ocular Melanoma UK came about to provide both support and a voice for those with this rare cancer. We bring people together across the country and provide UK-specific information.

Ocular melanoma is a rare cancer, and patients are frequently excluded from skin melanoma trials, which leaves research limited and reinforces the need for greater investment and understanding. As treatments progress, we remain committed to reducing the barriers that prevent people from receiving timely and appropriate care.

We are committed to ensuring that every patient has the information, support and treatment they need in a timely manner.

The main activities undertaken during the year to further the charity's purpose for the public benefit.

#### **Our aims and objectives**

Ocular Melanoma UK provides members and others with current information and non-clinical advice and support through various channels.

People tell us they wish they had learnt about us when they were first diagnosed, as they appreciate the information and support we provide. This means a great deal to them, so we have planned several projects to increase our reach so that once someone is diagnosed, they learn about Ocular Melanoma UK, the services we provide, and that we can encourage treatment pathways to be developed to ease the pressures people face.

## Ocular Melanoma UK

Company Registration Number - 8013670

### Trustees' Annual Report for the year ended 31 March 2025

***The main activities undertaken during the year to further the charity's purpose for the public benefit.***

During the year, we supported our community by offering the following services:

#### **To Improve Support**

##### Emotional & Practical Support

Our Head of Support is supporting more people through our helpline and manages our online community support groups. These are open to anyone affected by this cancer. The weekly meetings provide a safe place for people to give and receive support with any difficulties they face.

##### Psychological Support

Continued to provide members with timely & funded professional support with a specialist Health Psychologist to ease the impact this diagnosis can have. This allows patients and loved ones throughout the UK to access up to six funded sessions.

##### Health Information

We maintained our PIF TICK accreditation this year, which means our health information is easily recognised as a trusted source. Our resources are reviewed by clinicians to ensure accuracy and are developed with patients, so the content reflects what people genuinely want and need to know. We continue to extend the written information available to people.

With the launch of our new website, we created a dedicated section for trusted, clear and up-to-date information. It is arranged by stage to help people find what they need without feeling overwhelmed.

##### Community Support

As mentioned above, we run regular online sessions for people to come together to remove isolation and facilitate peer-to-peer support online. We continue to develop our local ambassador programme so that people can meet other members throughout the UK in person.

## Ocular Melanoma UK

Company Registration Number - 8013670

### Trustees' Annual Report for the year ended 31 March 2025

#### To Build Knowledge

##### Conference

We held a two-day conference, which was very well attended by patients and family members. Yet again, we had a record number of people who hadn't attended a conference before, and for some, it was the first time they met others with the same condition, which is a huge help in itself.

We also had many leading experts in their field share their knowledge with us, and ensured these talks were recorded and available after the event, so the latest knowledge could be easily shared.

##### Website

Our new website is in its second phase, with cancer-related information being reviewed, adhering to Pif-Tick quality standards and added to our site. Clinical trials have also been added and updated regularly with the support of our Clinical Advisory Panel.

##### Ocular Melanoma October

In October 2024, we launched Ocular Melanoma October, a month-long campaign to raise awareness about ocular melanoma and provide support to those affected by this rare cancer. The campaign featured educational content, community events, and culminated in the first Ocular Melanoma Day on 10 October, marking the charity's 15th anniversary. It resulted in a fourfold increase in our social media reach and connected individuals nationwide through in-person meetings. This success laid the foundation for an expanded awareness initiative next year, with funding already secured. Ocular Melanoma October will now become an annual tradition to amplify our impact and ensure no one faces ocular melanoma alone.

##### Bulletins

We produce a regular bulletin for our members giving updates on our work, how to access the services we provide, and, importantly, information on how people can share their experience with us or decision-makers to drive improvements.

##### Advocacy

We continued to advocate for patients and their families by making sure their voices shape national conversations on care, research and support. We contributed patient perspectives to research studies, engaged with clinicians and policymakers to highlight the realities of living with ocular melanoma, and ensured families were represented in service design discussions. Through our helpline, psychological support service and community forums, we gathered real-world insight that helped us challenge gaps in care and promote improvements across the pathway.

Our advocacy this year has centered on ensuring people have timely access to effective treatments, as reimbursement processes are harming patients. There is an unmet need in terms of treatment and with Chemosat being proven to be safe and effective, we are campaigning for this to be reviewed by NICE and NHS England, and subsequently funded on the NHS. We have repeatedly raised this and are now involving MPs to support our efforts.

The application to the SMC has not yet been submitted, but we are poised to mirror our campaigning in Scotland when it's appropriate.

##### Rare Community

Ocular Melanoma UK is a member of Cancer52 and Genetic Alliance and regularly attends NHS England Cancer Charity meetings so key messages can be communicated to our community, but also allows us to communicate the needs of people affected by ocular melanoma to decision-makers. Our CEO also works with Melanoma Patient Network for Europe and useMYdata, and sits on various projects to improve the lives of people with this cancer.

We have joined Cancer 52's Working Groups on Access to Medicines, Research and Data, as all of these areas should have a noticeable impact on our community.

## Ocular Melanoma UK

Company Registration Number - 8013670

### Trustees' Annual Report for the year ended 31 March 2025

#### To Drive Research

##### Clinical Advisory Panel

We have continued to work with our clinical advisory panel to gain their thoughts on how to resolve areas that are important to patients and to ensure the information we provide is clinically accurate.

##### Research applications

We supported several research applications that we felt would benefit people and met with organisations interested in learning about the impact of this cancer. At times, it was appropriate for us to lead those conversations, but where companies were interested in talking to patients directly, we reviewed the questions that would be asked and offered our support to the people involved.

##### Data

We have worked to improve the data routinely available to researchers and bodies such as NICE & SMC, and will continue to push for better data collection and sharing of data so that the needs of patients are clearly understood.

Our CEO spoke at Cancer Research UK's Data conference on the impact AI could have on care and how the needs of rare cancer patients should be considered, as we risk widening the survival gap between common and rare cancers.

##### Access to Medicines

We continued to build relationships with pharmaceutical companies that have an interest in this cancer to increase the number of trials available to people and to increase the possibility of effective treatments being made available to people.

We continue to encourage NHS England to allow chemosat to be funded and have supported patients while they appeal to private medical companies to have their decisions overturned.

##### Patient Need

We have expanded our reach so that more organisations understand that the needs of rare cancer patients are not being met with the current focus on improving mortality in the UK. We do this through working with organisations that share common goals and enable us to have a voice at a national level.

All this was achieved with the support of our donors and everyone who fundraised for us. We are incredibly grateful to everyone for their efforts over this challenging year, as it enabled us to continue our work and support people through some very difficult times.

The trustees have had regard to the Charity Commission's guidance on public benefit in managing the



## **Ocular Melanoma UK**

Company Registration Number - 8013670

### **Trustees' Annual Report for the year ended 31 March 2025**

#### **Structure, governance and management of the charity**

##### ***The methods used to recruit and appoint new charity trustees.***

##### **Governing Document**

The organisation is a charitable company limited by guarantee, incorporated on 30 March 2012 and registered as a charity on 30 May 2012. The company was established under a Memorandum of Association which established the objects and powers of the charitable company and is governed under its Articles of Association.

##### **Management Committee**

All Trustees gave and continue to give their time voluntarily and received no benefits from the charity. Any expenses reclaimed from the charity are set out in note 8 to the accounts. Trustees serve for up to three years and may be re-elected at the Annual General Meeting. The Board of Directors, together with the CEO, acts as the Management Committee.

##### **Trustee Induction**

Trustees have been appointed based on their ability to lead the Charity on behalf of the membership, and are a mix of people who either have existing knowledge of Ocular Melanoma, either as medical professional or patient or family of patient, or who bring necessary professional expertise.

Trustees are also directors registered with Companies House.

A comprehensive trustee information pack is supplied to each trustee, together with cross-references to the guidance published by the Charity Commission (for trustees) and by Companies House (for directors).

##### **Organisational Structure**

The Management Committee is responsible for the strategic direction and policy of the charity. The CEO has delegated responsibility from the Board for the overall operation of the charity.

##### **Bankers**

CAF Bank - Kings Hill, West Malling, Kent, ME19 4JQ

National Westminster Bank Plc, Earls Court, Enfield CSC, Lee House,

Bairs Road, Middlesex, EN1 1FD

Shawbrook Bank, Lutea House, Warley Hill Business Park, The Drive, Great Warley, Brentwood, Essex CM13 3BE

## Ocular Melanoma UK

Company Registration Number - 8013670

### Trustees' Annual Report for the year ended 31 March 2025

#### Financial review

##### *The charity's financial position at the end of the year ended 31 March 2025*

The financial position of the charity at 31 March 2025 and comparatives for the prior period, as more fully detailed in the accounts, can be summarised as follows:-

	2025 £	2024 £
Net income	7,442	(688)
Unrestricted Revenue Funds available for the general purposes of the charity	58,549	41,408
Restricted Revenue Funds	26,908	36,607
<b>Total Restricted Funds</b>	<b>26,908</b>	<b>36,607</b>
<b>Total Funds</b>	<b>85,457</b>	<b>78,015</b>

##### *Financial review of the position at the reporting date, 31 March 2025*

The trustees consider the financial performance by the charity during the year to have been satisfactory.

## **Ocular Melanoma UK**

Company Registration Number - 8013670

### **Trustees' Annual Report for the year ended 31 March 2025**

#### ***Policies on reserves***

This reserves policy aims to establish guidelines for the appropriate level of reserves that Ocular Melanoma UK should maintain. The reserves policy will help ensure that Ocular Melanoma UK has the financial resources to fulfil its mission and objectives, respond to emergencies, and manage risks. The reserves policy will also provide transparency and accountability to Ocular Melanoma UK's stakeholders, including donors, volunteers, staff, and beneficiaries.

##### **Nature of reserves:**

For the purposes of this policy, reserves are defined as funds that are held in excess of the immediate needs of Ocular Melanoma UK. Reserves include both unrestricted and restricted funds.

##### **Reserves Guidelines:**

1. **Target Reserves:** Ocular Melanoma UK should maintain a target reserve level equivalent to at least six months of operating expenses. The target reserves will be reviewed annually and adjusted as needed based on Ocular Melanoma UK's financial situation, risks, and opportunities.
2. **Minimum Reserves:** Ocular Melanoma UK should maintain a minimum level of reserves that is equivalent to three months of operating expenses. The minimum reserves will be reviewed annually and adjusted as needed based on Ocular Melanoma UK's financial situation, risks, and opportunities.
3. **Use of Reserves:** Reserves should only be used for specific purposes, such as emergencies, unexpected expenses, or to support new initiatives. Reserves should not be used to cover ongoing operational deficits or to fund programs that are not sustainable.
4. **Investment of Reserves:** Reserves should be invested in a prudent manner that balances safety, liquidity, and yield. The investment strategy should be reviewed annually and adjusted as needed based on Ocular Melanoma UK's financial situation, risks, and opportunities.
5. **Reporting on Reserves:** Ocular Melanoma UK will report annually on the status of its reserves in its financial statements. This reserves policy ensures that Ocular Melanoma UK has the financial resources to fulfil its mission and objectives, respond to emergencies, and manage risks.

The policy provides guidelines for the appropriate level of reserves, the use and investment of reserves, and reporting on reserves. The policy will be reviewed annually and adjusted as needed based on Ocular Melanoma UK's financial situation, risks, and opportunities.

#### ***Availability and adequacy of assets of each of the funds***

The board of trustees is satisfied that the charity's assets in each fund are available and adequate to fulfil its obligations in respect of each fund.

## Ocular Melanoma UK

Company Registration Number - 8013670

### Trustees' Annual Report for the year ended 31 March 2025

#### *Plans For the Future*

##### **Summary of plans for the future and the trustees' perspective of the future direction of the charity.**

We strive to improve the care, treatment and support that people receive.

In the year ahead, we will continue our work so that once someone is diagnosed, they learn about Ocular Melanoma UK and the services we provide, and that treatment pathways evolve to ease the pressures we know people face. We identified several ways to reduce these pressures, strengthening our charity so it can help people and their families through these difficult times.

In addition to the services outlined earlier in this report, we will continue to focus our efforts to:

1. Reduce delays in accessing treatment for metastatic disease and
2. Increase our services that reduce isolation and distress.

We will do this by:

##### **Improve Support**

- Allow patients to book scheduled helpline calls so they can access support at a time that feels manageable for them.
- Build a peer-to-peer network to support nurses and help them guide their patients throughout diagnosis and treatment.
- Continue to develop our suite of patient booklets and tailor this information for our website so people can easily find trusted, relevant information whenever they need it.
- Increase awareness of clinical trials by sharing all known studies on our website, recognising that there is no other single resource bringing these options together for our community.
- Introduce a chatbot on our website to help people quickly find information and support, particularly out of hours.

##### **Build Knowledge**

- Launch a survey to understand the day-to-day impact of ocular melanoma on people and their families, and make the insights widely available to support improvements in care and service design.
- Learn from the EUPATI Patient Expert Training Programme to strengthen our ability to contribute meaningfully to research discussions and ensure patient perspectives remain central to clinical decision making.
- Attend key meetings in the UK and abroad, including speaking at the Use MY Data conference, so the lived experience of ocular melanoma is represented wherever decisions are made.
- Represent our community across national and international forums, including NICE, SMC and NHS reviews, and through our CEO's role with EURACAN as the ePag for eye cancer.

## **Ocular Melanoma UK**

Company Registration Number - 8013670

### **Trustees' Annual Report for the year ended 31 March 2025**

#### **Drive Research**

- Begin a scheme to support early detection of ocular melanoma, recognising that in the absence of a cure, early diagnosis is one of the strongest opportunities to improve survival and quality of life.
- Continue to raise awareness of the disease so people are diagnosed sooner and have better access to timely treatment.
- Share real-world patient insight from our services, helping researchers and clinicians understand the challenges people face and shape studies that truly reflect patient needs.

#### **Be Sustainable**

- Expand the team to support our fundraisers and enable our Head of Marketing and Fundraising to plan work to support more people, including through initiatives such as Ocular Melanoma October.
- Encourage members to share how our support has helped them, strengthening our community and inspiring others to fundraise or get involved.
- Launch an overseas challenge event in response to member requests, helping diversify income and strengthen community engagement.
- Use all available resources wisely so our small team is positioned where it can have the greatest impact.
- Strengthen internal processes and digital tools, including the introduction of our new chatbot, to ensure we remain efficient, responsive and resilient as we grow.

Everything Ocular Melanoma UK has achieved continues to come from sheer dedication and a passion to make real change in the lives of those affected by this dreadful cancer.

We will continue until we have a world where people with ocular melanoma can live, and live well.

### **Details of The Independent Examiner**

Tracey Pritchard BA FCA  
Chartered Accountant  
255 Poulton Road  
Wallasey  
Merseyside  
CH44 4BT

## Ocular Melanoma UK

Company Registration Number - 8013670

### Trustees' Annual Report for the year ended 31 March 2025

#### Statement of the Directors Trustees' Responsibilities

The charity's trustees are responsible for the preparation of the accounts in accordance with the terms of the Companies Act 2006, the Charities Act 2011 and the Charities (Accounts and Reports) Regulations 2008. Notwithstanding the explicit requirement in the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008, to prepare the financial statements in accordance with the SORP 2005, in view of the fact that the SORP 2005 has been withdrawn, the Trustees determined to interpret this responsibility as requiring them to follow current best practice and prepare the accounts according to the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), .

In particular, the Companies Act 2006 and charity law require the Board of Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity as at the end of the financial year and of the surplus or deficit of the charity. In preparing those financial statements the Board is required to :-

- prepare the accounts in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law).
- select suitable accounting policies and apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business;
- state whether applicable accounting standards and statements of recommended practice have been followed, subject to any material departures disclosed and explained in the financial statements;

The law requires that the trustees must not approve the accounts unless they are satisfied that they give a true and fair view of the state of affairs of the charity and of the surplus or deficit of the charity for the year.

The Trustees are also responsible for maintaining adequate accounting records which disclose with reasonable accuracy at any time the financial position of the charity and which are sufficient to show and explain the charity's transactions and enable them to ensure that the financial statements comply with the Companies Act 2006 and comply with regulations made under the Charities Act. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are also responsible for the contents of the Trustees' report, and the statutory responsibility of the Independent Examiner in relation to the Trustees' report is limited to examining the report and ensuring that , on the face of the report, there are no material inconsistencies with the figures disclosed in the financial statements.

**Ocular Melanoma UK**

Company Registration Number - 8013670

**Trustees' Annual Report for the year ended 31 March 2025**

**Method of preparation of accounts - Small company provisions**

The financial statements are set out on pages 16 to 35.

The financial statements have been prepared implementing the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016)

These financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006, applicable to companies subject to the small companies regime.

This report was approved by the board of trustees on 18/12/ 2025.



MRS C EDWARDS  
Director and Trustee

## **Ocular Melanoma UK**

### **Report of the Independent Examiner to the Trustees of the charitable company on the accounts for the year ended 31 March 2025**

I report to the Trustees on my examination of the financial statements of the charitable company on pages 16 to 35 for the year ended 31 March 2025 which have been prepared in accordance with the Charities Act 2011 (the Act) and with the Financial Reporting Standard 102, (effective 1st January 2016) as modified by FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , and under the historical cost convention and the accounting policies set out on page 21.

#### **Respective responsibilities of the Trustees and the Independent Examiner and the basis of the report**

As described on page 12, you, the charitable company's Trustees, who are also the Directors of the Company for the purposes of Company law, are responsible for the preparation of the financial statements in accordance with the Companies Act 2006, the Charities Act 2011 and all other applicable law and with United Kingdom Generally Accepted Accounting Practice, applicable to smaller entities, and for being satisfied that the financial statements give a true and fair view.

The Trustees consider that the audit requirement of Section 144(1) of the Charities Act 2011 (the Act) does not apply, and that there is no requirement in the memorandum and articles of the charity for the conducting of an audit, and that the accounts do not require an audit in accordance with Part 16 of the Companies Act 2006 and that no member or members have requested an audit pursuant to Section 476 of the Companies Act 2006. As a consequence, the Trustees have elected that the financial statements be subject to independent examination.

Having satisfied myself that the financial statements are not required to be audited under any legal provision, or otherwise, and are eligible for independent examination, it is my responsibility to:-

- a) examine the financial statements of the charity under Section 145 of the Act;
- b) follow the applicable procedures in the Directions given by the Charity Commission under section 145(5)(b) of the Act.

#### **Basis of Independent Examiner's Statement and scope of work undertaken**

I report in respect of my examination of the charity's financial statements carried out under s145 of the Act. In carrying out my examination, I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act setting out the duties of an independent examiner in relation to the conducting of an independent examination. An independent examination includes a review of the accounting records kept by the charitable company and of the accounting systems employed by the charitable company and a comparison of the financial statements presented with those records. It also includes consideration of any unusual items or disclosures in the financial statements, and seeking explanations from you, as Trustees, concerning such matters. The purpose of the examination is to establish as far as possible that there have been no breaches of charity legislation and that, on a test basis of evidence relevant to the amounts and disclosures made, the financial statements comply with the SORP.

The procedures undertaken do not provide all the evidence that would be required in an audit, and information supplied by the Trustees in the course of the examination is not subjected to audit tests or enquiries and does not cover all the matters that an auditor would consider in arriving at an opinion. The planning and conduct of an audit goes beyond the limited assurance that an independent examination can provide

Consequently, I do not express an audit opinion on the view given by the financial statements, and in particular, I express no opinion as to whether the financial statements give a true and fair view of the affairs of the charity, and my report is limited to the matters set out in the statement below.

I planned and performed my examination so as to satisfy myself that the objectives of the independent examination are achieved and before finalising the report I obtained written assurances from the Trustees of all material matters.



## Ocular Melanoma UK

### Independent Examiner's Statement, Report and Opinion

Subject to the limitations upon the scope of my work as detailed above, I have completed my examination: and can confirm that:-

The accounts of this charitable company are not required to be audited under Part 16 of the Companies Act 2006;

This is a report in respect of an examination carried out under 145 of the Act and in accordance with Directions given by the Charity Commission under section 145(5)(b) of the Act which may be applicable;

and that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:-

accounting records were not kept in respect of the charity as required by Section 386 of the Companies Act 2006 and Section 130 of The Charities Act 2011;

the financial statements do not accord with those records; or

the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in section 396 of the Companies Act 2006 other than any requirement that the accounts give a 'true and fair' view, which is not a matter considered as part of an independent examination;

have not been prepared in accordance with the methods and principles set out in the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Signed:-



Tracey Pritchard BA FCA - Independent Examiner

Chartered Accountant

255 Poulton Road  
Wallasey  
Merseyside  
CH44 4BT

This report was signed on 18/12/ 2025

## Ocular Melanoma UK - Statement of Financial Activities for the year ended 31 March 2025

*Statement of Financial Activities (including the Income and Expenditure Account for the year ended 31 March 2025, as required by the Companies Act 2006)*

	SORP Ref	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2025 £	2025 £	2025 £	2024 £
<b>Income &amp; Endowments from:</b>					
Donations & Legacies	A1	56,302	69,884	126,186	103,133
Charitable activities	A2	247	-	247	325
Other trading activities	A3	53,531	-	53,531	45,317
Investments	A4	939	-	939	520
<b>Total income</b>	<b>A</b>	<b>111,019</b>	<b>69,884</b>	<b>180,903</b>	<b>149,295</b>
<b>Expenditure on:</b>					
Raising funds	B1	6,777	-	6,777	2,972
Charitable activities	B2	87,101	79,583	166,684	147,011
<b>Total expenditure</b>	<b>B</b>	<b>93,878</b>	<b>79,583</b>	<b>173,461</b>	<b>149,983</b>
<b>Net income for the year</b>		<b>17,141</b>	<b>(9,699)</b>	<b>7,442</b>	<b>(688)</b>
<b>Transfers between funds</b>	<b>C</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Net income after transfers</b>	<b>A-B-C</b>	<b>17,141</b>	<b>(9,699)</b>	<b>7,442</b>	<b>(688)</b>
<b>Net movement in funds</b>		<b>17,141</b>	<b>(9,699)</b>	<b>7,442</b>	<b>(688)</b>
<b>Reconciliation of funds:-</b>					
<b>Total funds brought forward</b>	<b>E</b>	<b>41,408</b>	<b>36,607</b>	<b>78,015</b>	<b>78,703</b>
<b>Total funds carried forward</b>		<b>58,549</b>	<b>26,908</b>	<b>85,457</b>	<b>78,015</b>

The 'SORP Ref' indicated above is the classification of income set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the Balance Sheet.

A separate Statement of Total Recognised Gains and Losses is not required as this statement includes all recognised gains and losses.

All activities derive from continuing operations

**The notes attached on pages 21 to 35 form an integral part of these accounts.**

## Ocular Melanoma UK - Statement of Financial Activities for the year ended 31 March 2025

### Ocular Melanoma UK - Analysis of prior year total funds, as required by paragraph 4.2 of the SORP

	SORP Ref	Prior Year Unrestricted Funds 2024 £	Prior Year Restricted Funds 2024 £	Prior Year Total Funds 2024 £
<b>Income &amp; Endowments from:</b>				
Donations & Legacies	A1	42,133	61,000	103,133
Charitable activities	A2	325	-	325
Other trading activities	A3	45,317	-	45,317
Investments	A4	520	-	520
<b>Total income</b>	<b>A</b>	<b>88,295</b>	<b>61,000</b>	<b>149,295</b>
<b>Expenditure on:</b>				
Raising funds	B1	2,972	-	2,972
Charitable activities	B2	90,800	56,211	147,011
<b>Total expenditure</b>	<b>B</b>	<b>93,772</b>	<b>56,211</b>	<b>149,983</b>
Net gains on investments	B4	-	-	-
<b>Net income for the year</b>		<b>(5,477)</b>	<b>4,789</b>	<b>(688)</b>
Transfers between funds	C			-
<b>Net income after transfers</b>		<b>(5,477)</b>	<b>4,789</b>	<b>(688)</b>
<b>Net movement in funds</b>		<b>(5,477)</b>	<b>4,789</b>	<b>(688)</b>
<b>Reconciliation of funds:-</b>				
<b>Total funds brought forward</b>	<b>E</b>	<b>54,910</b>	<b>23,793</b>	<b>78,703</b>
<b>Total funds carried forward</b>		<b>49,433</b>	<b>28,582</b>	<b>78,015</b>

## Ocular Melanoma UK - Statement of Financial Activities for the year ended 31 March 2025

### Ocular Melanoma UK - Resources applied in the year ended 31 March 2025 towards fixed assets for Charity use:-

	2025 £	2024 £
Funds generated in the year as detailed in the SOFA	7,442	(688)
Resources applied on functional fixed assets	-	-
Other applications of funds	-	-
<b>Net resources available to fund charitable activities</b>	<b>7,442</b>	<b>(688)</b>

The resources applied on fixed assets for charity use represents the cost of additions less proceeds of any disposals.

The notes attached on pages 21 to 35 form an integral part of these accounts.

### Movements in revenue and capital funds for the year ended 31 March 2025

#### Revenue accumulated funds

	Unrestricted Funds 2025 £	Restricted Funds 2025 £	Total Funds 2025 £	Last year Total Funds 2024 £
Accumulated funds brought forward	41,408	36,607	78,015	78,703
Recognised gains and losses before transfers	17,141	(9,699)	7,442	(688)
	<b>58,549</b>	<b>26,908</b>	<b>85,457</b>	<b>78,015</b>
(From)/To unrestricted revenue funds	-	-	-	-
<b>Closing revenue funds</b>	<b>58,549</b>	<b>26,908</b>	<b>85,457</b>	<b>78,015</b>

#### Summary of funds

	Unrestricted and Designated funds 2025 £	Restricted Funds 2025 £	Total Funds 2025 £	Last Year Total Funds 2024 £
Revenue accumulated funds	58,549	26,908	85,457	78,015

The notes attached on pages 21 to 35 form an integral part of these accounts.

## Ocular Melanoma UK - Statement of Financial Activities for the year ended 31 March 2025

### Ocular Melanoma UK Income and Expenditure Account for the year ended 31 March 2025 as required by the Companies Act 2006

	2025 £	2024 £
<b>Income</b>		
Income from operations	179,964	148,775
Investment income		
Interest receivable	939	520
<b>Gross income in the year before exceptional items</b>	<b>180,903</b>	<b>149,295</b>
<b>Gross income in the year including exceptional items</b>	<b>180,903</b>	<b>149,295</b>
<b>Expenditure</b>		
Charitable expenditure, excluding depreciation and amortisation	165,318	145,598
Depreciation and amortisation	142	243
Fundraising costs	6,777	2,972
Governance costs	1,224	1,170
<b>Total expenditure in the year</b>	<b>173,461</b>	<b>149,983</b>
<b>Net income before tax in the financial year</b>	<b>7,442</b>	<b>(688)</b>
Tax on surplus on ordinary activities	-	-
<b>Net income after tax in the financial year</b>	<b>7,442</b>	<b>(688)</b>
<b>Retained surplus for the financial year</b>	<b>7,442</b>	<b>(688)</b>

All activities derive from continuing operations

In accordance with the provisions of the Companies Act 2006, the headings and subheadings used in the Income and Expenditure account have been adapted to reflect the special nature of the charity's activities.

The notes attached on pages 21 to 35 form an integral part of these accounts.

Ocular Melanoma UK - Balance Sheet as at 31 March 2026

	SORP Note Ref	2025 £	2024 £
<b>Fixed assets</b>	A		
Tangible assets	10 A2	96	238
<b>Current assets</b>	B		
Stocks	11 B1	4,386	2,108
Debtors	12 B2	22,884	-
Cash at bank and in hand	B4	59,827	77,273
<b>Total current assets</b>		<u>87,097</u>	<u>79,381</u>
<b>Creditors: amounts falling due within one year</b>	13 C1	<u>(1,736)</u>	<u>(1,604)</u>
<b>Net current assets</b>		85,361	77,777
<b>The total net assets of the charity</b>		<u><b>85,457</b></u>	<u><b>78,015</b></u>

The total net assets of the charity are funded by the funds of the charity, as follows:-

<b>Restricted funds</b>			
Restricted Revenue Funds	17 D2	26,908	36,607
		26,908	36,607
<b>Unrestricted Funds</b>			
Unrestricted Revenue Funds	17 D3	58,549	41,408
		<u>58,549</u>	<u>41,408</u>
<b>Total charity funds</b>		<u><b>85,457</b></u>	<u><b>78,015</b></u>

The 'SORP Ref' indicated above is the classification of Balance Sheet items as set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the SOFA.

The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit in accordance with section 476 of the Act.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

The charity is subject to Independent Examination under charity legislation, and the report of the Independent Examiner is on page 15.

The financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006, applicable to companies subject to the small companies regime.



MRS C EDWARDS

Trustee

Approved by the board of trustees on 18/12/2025

The notes attached on pages 21 to 35 form an integral part of these accounts.

## Ocular Melanoma UK

### Notes to the Accounts for the year ended 31 March 2025

#### 1 Accounting policies

##### *Policies relating to the production of the accounts.*

##### **Basis of preparation and accounting convention**

The accounts have been prepared on the accruals basis, under the historical cost convention, and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016) and 'FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW), effective January 2016, and in accordance with all applicable law in the charity's jurisdiction of registration, except that the charity has prepared the financial statements in accordance with the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), in preference to the previous SORP, the SORP 2005, which has been withdrawn, notwithstanding the fact that the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008 refer explicitly to the SORP 2005. This has been done to accord with current best practice.

##### **Risks and future assumptions**

The charity is a public benefit entity.

The Management Committee has reviewed the major risks to which the charity has been exposed. Where appropriate, systems or procedures have been established to mitigate the risks the charity faces.

Our Regional Representatives are each issued with the Ocular Melanoma UK Representative Handbook and are invited to attend a training session.

Financial control risks are minimised by the implementation of procedures for authorisation of all transactions.

##### **Accounting for deferred income and income received in advance**

Where terms and conditions relating to income have not been met or uncertainty exists as to whether the charity can meet any terms or conditions otherwise within its control, income is not recognised but is deferred as a liability until it is probable that the terms or conditions imposed can be met.

Any grant that is subject to performance-related conditions received in advance of delivering the goods and services required by that condition, or is subject to unmet conditions wholly outside the control of the recipient charity, is accounted for as a liability and shown on the balance sheet as deferred income. Deferred income is released to income in the reporting period in which the performance-related or other conditions that limit recognition are met.

When income from a grant or donation has not been recognised due to the conditions applying to the gift not being wholly within the control of the recipient charity, it is disclosed as a contingent asset if receipt of the grant or donation is probable once those conditions are met.

Where time related conditions are imposed or implied by a funder, then the income is apportioned to the time periods concerned, and, where applicable, is accounted for as a liability and shown on the balance sheet as deferred income. When grants are received in advance of the expenditure on the activity funded by them, but there are no specific time related conditions, then the income is not deferred.

Any condition that allows for the recovery by the donor of any unexpended part of a grant does not prevent recognition of the income concerned, but a liability to any repayment is recognised when repayment becomes probable.

## Ocular Melanoma UK

### Notes to the Accounts for the year ended 31 March 2025

#### Donated goods, facilities and services

Donated fixed assets are recognised at the current fair value. All such donations are recognised as donation income, and debited to fixed assets.

Donated goods that are not fixed assets are accounted for at a fair value, unless it is impractical to reliably measure the value of the donated items.

In the absence of any direct evidence of fair value of donated goods, then a value is derived from the cost of the item to the donor or, in the case of goods that are expected to be sold, the estimated resale value after deducting any anticipated costs of sales.

If it is impracticable to measure the fair value of goods donated for resale, or the costs of valuation outweigh the benefits, the donated goods are recognised as income when sold, with an equivalent amount being recognised as an expense.

The costs of goods donated for distribution to beneficiaries is deemed to be the fair value of those goods upon receipt. When the goods are distributed freely or for a nominal consideration, then the carrying amount is adjusted at the time of sale, to the value at the point of distribution and the adjustment is shown as a cost of donations made.

The carrying amount of any stock held for distribution is assessed for impairment at the reporting date. All donated goods are recognised as donation income, and debited to trading stock. When trading stock is subsequently sold, or appropriated to meet an expense, then the carrying value of the stock is recognised as an expense. In accordance with the SORP, goods donated for distribution to beneficiaries, or for consumption by the charity are included in 'legacies and donations'. Goods donated for resale are included in 'Income from other trading activities'.

The cost of any stock of goods donated for distribution to beneficiaries is deemed to be the fair value of those gifts at the time of their receipt. If the goods held are to be distributed freely or for a nominal consideration, then the carrying amount is subsequently adjusted to reflect the lower of deemed cost adjusted for any loss of service potential and replacement cost. Replacement cost is the economic cost incurred if the charity was to replace the service potential of the donated goods at its own expense in the most economic manner.

Donated services and facilities (including seconded staff and use of property) are included in the accounts on the basis of the value of the gift to the charity.

All donated services and facilities are recognised as donation income when received, (provided the value of the gift can be measured reliably) and recognised as an expense with an equivalent value.

#### ***Policies relating to assets, liabilities and provisions and other matters.***

##### ***Tangible fixed assets***

Tangible fixed assets are measured at their original cost value, or subsequent revaluation, or if donated, as described above. Cost value includes all costs expended in bringing the asset into its intended working condition.

Depreciation has been provided at the following rates in order to write off the assets to their anticipated residual value over their estimated useful lives.

Plant and machinery	over 3 years
---------------------	--------------

A regular annual review of the likelihood of asset impairment is undertaken.

##### **Stocks and work in progress**

Stock is valued at the lower of cost and net realisable value.

##### **Fund Accounting**

Unrestricted funds are available for use at the discretion of the trustees in furtherance of the general objectives of the charity.

There are no endowment funds.



## Ocular Melanoma UK

### Notes to the Accounts for the year ended 31 March 2025

#### 2 Liability to taxation

The Trustees consider that the charity satisfies the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by chapter 3 part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively on the specific charitable objects of the charity and for no other purpose. Value Added Tax is not recoverable by the charity, and is therefore included in the relevant costs in the Statement of Financial Activities.

#### 3 Winding up or dissolution of the charity

If upon winding up or dissolution of the charity there remain any assets, after the satisfaction of all debts and liabilities, the assets represented by the accumulated fund shall be transferred to some other charitable body or bodies having similar objects to the charity.

#### 4 Significance of financial instruments to the charity's position

There are no significant implications of such matters

#### 5 Net surplus before tax in the financial year

	2025 £	2024 £
The net surplus before tax in the financial year is stated after charging:-		
Depreciation of owned fixed assets	142	243
Pension costs	2,429	3,886

#### 6 Staff costs and emoluments

<i>Salary costs</i>	2025 £	2024 £
Gross Salaries excluding trustees and key management personnel	82,885	97,851
Employer's operating costs of defined contribution pension schemes	2,429	3,886
<b>Total salaries, wages and related costs</b>	<b>85,314</b>	<b>101,737</b>

The average number of full time staff employed in the year was	1	1
The estimated full time equivalent number of all staff employed in the year was	3	3

#### *The estimated equivalent number of full time staff deployed in different activities in the year was:-*

Engaged on charitable activities	3	3
<b>The estimated full time equivalent number of all staff employed as above</b>	<b>3</b>	<b>3</b>

Neither the trustees nor any persons connected with them have received any remuneration from the charity or any related entity, either in the current or prior year.

No employees received emoluments (excluding pension costs) in excess of £60,000 per annum.

#### 7 Defined contribution pension schemes

Any liabilities and assets associated with the scheme are shown under debtors and creditors.

## Ocular Melanoma UK

### Notes to the Accounts for the year ended 31 March 2025

#### 8 Remuneration and payments to Trustees and persons connected with them

	2025	2024
	£	£
<i>Remuneration payable to trustees or connected persons</i>		
No trustees or connected persons received remunerations.	-	-

#### 9 Trustees' expenses

No trustee expenses were incurred, either in the current or prior year.

#### 10 Tangible fixed assets

<i>Current Year</i>	Land and Buildings	Plant & Machinery	Motor Vehicles	Total
	£	£	£	£
<b>Cost</b>				
At 1 April 2024	-	3,552	-	3,552
Additions	-	-	-	-
<b>At 31 March 2025</b>	<b>-</b>	<b>3,552</b>	<b>-</b>	<b>3,552</b>
<b>Depreciation</b>				
At 1 April 2024	-	3,314	-	3,314
Charge for the year	-	142	-	142
<b>At 31 March 2025</b>	<b>-</b>	<b>3,456</b>	<b>-</b>	<b>3,456</b>
<b>Net book value</b>				
<b>At 31 March 2025</b>	<b>-</b>	<b>96</b>	<b>-</b>	<b>96</b>
<b>At 31 March 2024</b>	<b>-</b>	<b>238</b>	<b>-</b>	<b>238</b>
<i>Prior Year</i>	Land and Buildings	Plant & Machinery	Motor Vehicles	Total
	£	£	£	£
<b>Cost</b>				
01 April 2023	-	3,552	-	3,552
Additions	-	-	-	-
<b>31 March 2024</b>	<b>-</b>	<b>3,552</b>	<b>-</b>	<b>3,552</b>
<b>Depreciation</b>				
01 April 2023	-	3,071	-	3,071
Charge for the year	-	243	-	243
<b>31 March 2024</b>	<b>-</b>	<b>3,314</b>	<b>-</b>	<b>3,314</b>
<b>Net book value</b>				
<b>31 March 2024</b>	<b>-</b>	<b>238</b>	<b>-</b>	<b>238</b>
<b>01 April 2023</b>	<b>-</b>	<b>481</b>	<b>-</b>	<b>481</b>

## Ocular Melanoma UK

### Notes to the Accounts for the year ended 31 March 2025

#### 11 Stocks & Work in Progress

	2025 £	2024 £
Stocks before write downs	4,386	2,108
	<u>4,386</u>	<u>2,108</u>

#### 12 Debtors

	2025 £	2024 £
Trade debtors	22,884	-
	<u>22,884</u>	<u>-</u>

#### 13 Creditors: amounts falling due within one year

	2025 £	2024 £
Trade creditors	776	644
Accruals	960	960
	<u>1,736</u>	<u>1,604</u>

#### 14 Income and Expenditure account summary

	2025 £	2024 £
At 1 April 2024	78,015	78,703
Surplus after tax for the year	7,442	(688)
At 31 March 2025	<u>85,457</u>	<u>78,015</u>

#### 15 No related party transactions

No trustee or other person related to the charity had any personal interest in any contract or transaction entered into by the charity during the year.

#### 16 Particulars of how particular funds are represented by assets and liabilities

##### At 31 March 2025

	Unrestricted funds £	Designated funds £	Restricted funds £	Total Funds £
Tangible Fixed Assets	96	-	-	96
Current Assets	60,189	-	26,908	87,097
Current Liabilities	(1,736)	-	-	(1,736)
	<u>58,549</u>	<u>-</u>	<u>26,908</u>	<u>85,457</u>

##### At 1 April 2024

	Unrestricted funds £	Designated funds £	Restricted funds £	Total Funds £
Tangible Fixed Assets	238	-	-	238
Current Assets	42,774	-	36,607	79,381
Current Liabilities	(1,604)	-	-	(1,604)
	<u>41,408</u>	<u>-</u>	<u>36,607</u>	<u>78,015</u>

## Ocular Melanoma UK

### Notes to the Accounts for the year ended 31 March 2025

#### 17 Change in total funds over the year as shown in Note 16 , analysed by individual funds

	Funds brought forward from 2024	Movement in funds in 2025	Transfers between funds in 2025	Funds carried forward to 2026
	£	See Note 18 £	£	£
<b>Unrestricted and designated funds:-</b>				
Unrestricted Revenue Funds	41,408	17,141	-	58,549
<b>Total unrestricted and designated funds</b>	<b>41,408</b>	<b>17,141</b>	<b>-</b>	<b>58,549</b>
<b>Restricted funds:-</b>				
Annual Conference	7,167	(6,667)	-	500
Patient folder	3,675	-	-	3,675
Patient Information to PifTick standard	1,883	(173)	-	1,710
Resources HCP	2,333	1,768	-	4,101
Trial Database	2,333	125	-	2,458
Helpline Advisor Role and Support	10,544	(6,069)	-	4,475
Psychological Support	4,839	817	-	5,656
Educational Event	3,833	500	-	4,333
<b>Total restricted funds</b>	<b>36,607</b>	<b>(9,699)</b>	<b>-</b>	<b>26,908</b>
<b>Total charity funds</b>	<b>78,015</b>	<b>7,442</b>	<b>-</b>	<b>85,457</b>

#### 18 Analysis of movements in funds over the year as shown in Note 17

	Income	Expenditure	Other Gains & Losses	Movement in funds
	2025 £	2025 £	2025 £	2025 £
<b>Unrestricted and designated funds:-</b>				
Unrestricted Revenue Funds	111,019	(93,878)	-	17,141
<b>Restricted funds:-</b>				
Conference	24,349	(31,016)	-	(6,667)
Patient folder	-	-	-	-
Patient Information to PifTick standard	16,700	(16,873)	-	(173)
Resources HCP	1,900	(132)	-	1,768
Trial Database	1,900	(1,775)	-	125
Helpline Advisor Role and Support	14,035	(20,104)	-	(6,069)
Psychological Support	10,500	(9,683)	-	817
Educational Event	500	-	-	500
	<b>180,903</b>	<b>(173,461)</b>	<b>-</b>	<b>7,442</b>

## Ocular Melanoma UK

### Notes to the Accounts for the year ended 31 March 2025

#### 19 The purposes for which the funds are

##### *Unrestricted and designated funds:-*

Unrestricted Revenue Funds

These funds are held for the meeting the objectives of the charity, and to provide reserves for future activities, and, subject to charity legislation, are free from all restrictions on their use.

##### *Restricted funds:-*

Restricted Revenue Funds:

Restricted funds are funds that donors have given for a particular purpose and/or project as outlined by donors and may include other connected costs. The aim and use of each restricted fund are detailed in the notes of the financial statements.

#### 20 Ultimate controlling party

The charity is under the control of its legal members.

Every member of the charity is obliged to contribute such amount as may be required not exceeding £10 to the assets of the company in the event of its being wound up while he or she is a member, or within one year after he or she ceases to be a member.

## Ocular Melanoma UK

Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015

*This analysis is classssified by conventional nominal descriptions and not by activity.*

### 21 Donations, Grants and Legacies

	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2025	2025	2025	2024
	£	£	£	£
Small donations individually less than £1000	30,057	-	30,057	21,996
anonymous donors	2,943	-	2,943	2,329
CLS UK	-	-	-	1,000
In Memory	10,802	-	10,802	13,786
<b>Total donations and gifts from individuals</b>	<b>43,802</b>	<b>-</b>	<b>43,802</b>	<b>39,111</b>

Donations and gifts from individuals (Include HMRC refunds on gift aided donations) - Prior Year analysis

	Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds	
	2024	2024	2024	
	£	£	£	
Prior year	39,111	-	39,111	

  

	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2025	2025	2025	2024
	£	£	£	£
Legacies receivable				
IM JH	10,000	-	10,000	-
<b>Total legacies receivable</b>	<b>10,000</b>	<b>-</b>	<b>10,000</b>	<b>-</b>

Legacies receivable - Prior Year analysis

	Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
	2024	2024	2024
	£	£	£
Prior year	-	-	-

## Ocular Melanoma UK

Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015

### Revenue grants and donations from non public bodies

	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2025	2025	2025	2024
	£	£	£	£
Delcath Systems Ltd	-	15,000	15,000	11,000
Immunocore Limited	-	32,000	32,000	32,000
Aura Biosciences	-	22,884	22,884	-
Vision Foundation	-	-	-	9,000
Alan Boswell Charity ALA	-	-	-	3,022
Souter Charitable Trust	-	-	-	3,000
TriSalus Life Science	-	-	-	3,000
Ideaya Biosciences	2,500	-	2,500	3,000
<b>Total private sector revenue grants</b>	<b>2,500</b>	<b>69,884</b>	<b>72,384</b>	<b>64,022</b>

### Revenue grants and donations from non public bodies (Include Gift Aid donations from subsidiaries) - Prior Year analysis

	Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
	2024	2024	2024
	£	£	£
<b>Prior Year</b>	<b>3,022</b>	<b>61,000</b>	<b>64,022</b>

## Ocular Melanoma UK

Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015

### Total Donations, Grants and Legacies

<i>Current year</i>		Unrestricted Funds	Restricted Funds	Current Year Total Funds	Prior Year Total Funds
		2025	2025	2025	2024
		£	£	£	£
<b>Total Donations, Grants and Legacies</b>	<b>A1</b>	<b>56,302</b>	<b>69,884</b>	<b>126,186</b>	<b>103,133</b>
<i>Prior year</i>		Unrestricted Funds	Restricted Funds	Prior Year Total Funds	
		2024	2024	2024	
		£	£	£	
<b>Total Donations, Grants and Legacies</b>	<b>A1</b>	<b>42,133</b>	<b>61,000</b>	<b>103,133</b>	

### 22 Income from charitable activities - Trading Activities

<i>Current year</i>		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total funds
		2025	2025	2025	2024
		£	£	£	£
<b>Primary purpose and ancillary trading</b>					
Sale of goods and services in accordance with the charity's objects		247	-	247	325
<b>Total Primary purpose and ancillary trading</b>		<b>247</b>	<b>-</b>	<b>247</b>	<b>325</b>
<i>Prior year</i>		Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds	
		2024	2024	2024	
		£	£	£	
<b>Primary purpose and ancillary trading</b>					
Sale of goods and services in accordance with the charity's objects		325	-	325	
<b>Total Primary purpose and ancillary trading</b>		<b>325</b>	<b>-</b>	<b>325</b>	



## Ocular Melanoma UK

### Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015

#### 23 Total Income from charitable activities

<i>Current year</i>	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2025	2025	2025	2024
	£	£	£	£
Total income from charitable trading	247	-	247	325
<b>Total from charitable activities      A2</b>	<b>247</b>	<b>-</b>	<b>247</b>	<b>325</b>

#### Income from charitable activities - Prior Year analysis

<i>Prior year</i>	Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
	2024	2024	2024
	£	£	£
Total income from charitable trading	325	-	325
	<b>325</b>	<b>-</b>	<b>325</b>

## Ocular Melanoma UK

Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015

### 24 Income from other, non charitable, trading activities

	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2025	2025	2025	2024
	£	£	£	£
Income from fundraising events	53,531	-	53,531	45,317
<b>Total from other activities</b>	<b>53,531</b>	<b>-</b>	<b>53,531</b>	<b>45,317</b>

### Income from other, non charitable, trading activities - Prior Year analysis

	Unrestricted Funds	Restricted Funds	Total Funds
Prior Year	45,317	-	45,317

## Ocular Melanoma UK

Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015

### 25 Expenditure on charitable activities - Direct spending

<b>Current Year</b>	<b>Current year Unrestricted Funds</b>	<b>Current year Restricted Funds</b>	<b>Current year Total Funds</b>	<b>Prior Year Total Funds</b>
	<b>2025</b>	<b>2025</b>	<b>2025</b>	<b>2024</b>
	<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>
Gross wages and salaries - charitable activities	59,777	23,108	82,885	97,851
Defined contribution pension costs - charitable activities	2,429	-	2,429	3,886
Travel and Subsistence - Charitable Activities	2,828	-	2,828	747
Marketing and advertising of charitable services	3,918	1,332	5,250	118
Charitable activities costs	2,253	52,475	54,728	26,706
Staff welfare	261	-	261	-
<b>Total direct spending</b>	<b>71,466</b>	<b>76,915</b>	<b>148,381</b>	<b>129,308</b>

All the expenditure in the prior year was unrestricted.

<b>Prior Year</b>	<b>Prior Year Unrestricted Funds</b>	<b>Prior Year Restricted Funds</b>	<b>Prior Year Total Funds</b>
	<b>2024</b>	<b>2024</b>	<b>2024</b>
	<b>£</b>	<b>£</b>	<b>£</b>
Gross wages and salaries - charitable activities	66,951	30,900	97,851
Defined contribution pension costs - charitable activities	3,886	-	3,886
Travel and Subsistence - Charitable Activities	747	-	747
Marketing and advertising of charitable services	118	-	118
Charitable activities costs	1,395	25,311	26,706
<b>Total direct spending</b>	<b>73,097</b>	<b>56,211</b>	<b>129,308</b>

## Ocular Melanoma UK

Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015

### 26 Support costs for charitable activities

<i>Current Year</i>	Current year Unrestricted Funds 2025 £	Current year Restricted Funds 2025 £	Current year Total Funds 2025 £	Prior Year Total Funds 2024 £
<b><i>Employee costs not included in direct costs</i></b>				
Recruitment expenses	-	-	-	256
<b><i>Administrative overheads</i></b>				
Telephone, fax and internet	161	1,788	1,949	1,885
Stationery and printing	257	-	257	597
Membership subscriptions	2,959	-	2,959	2,662
Software licences and expenses	5,308	-	5,308	2,682
Sundry expenses	32	-	32	-
Insurance	1,019	-	1,019	907
<b><i>Professional fees paid to advisors other than the auditor or examiner</i></b>				
Accountancy fees other than examination or audit fees	952	880	1,832	1,772
Other legal and professional	3,484	-	3,484	5,363
<b><i>Financial costs</i></b>				
Bank charges	97	-	97	132
Depreciation & Amortisation in total for the period	142	-	142	243
<b>Support costs before reallocation</b>	<b>14,411</b>	<b>2,668</b>	<b>17,079</b>	<b>16,499</b>
<b>Total support costs - Current Year</b>	<b>14,411</b>	<b>2,668</b>	<b>17,079</b>	<b>16,499</b>

The basis of allocation of costs between activities is described under accounting policies  
All the expenditure in the prior year was unrestricted.

### 27 Other Expenditure - Governance costs

<i>Current Year</i>	Current year Unrestricted Funds 2025 £	Current year Restricted Funds 2025 £	Current year Total Funds 2025 £	Prior Year Total Funds 2024 £
Independent Examiner's fees	1,224	-	1,224	1,170
<b>Total Governance costs</b>	<b>1,224</b>	<b>-</b>	<b>1,224</b>	<b>1,170</b>

All the expenditure in the prior year was unrestricted.

## Ocular Melanoma UK

Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015

### 28 Total Charitable expenditure

<i>Current Year</i>		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2025 £	2025 £	2025 £	2024 £
Total direct spending	<b>B2a</b>	71,466	76,915	148,381	129,308
Total charitable trading costs	<b>B2b</b>	-	-	-	34
Total support costs	<b>B2d</b>	14,411	2,668	17,079	16,499
Total Governance costs	<b>B2e</b>	1,224	-	1,224	1,170
<b>Total charitable expenditure</b>	<b>B2</b>	<b>87,101</b>	<b>79,583</b>	<b>166,684</b>	<b>147,011</b>
<i>Prior Year</i>		Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds	
		2024 £	2024 £	2024 £	
Total direct spending	<b>B2a</b>	73,097	56,211	129,308	
Total charitable trading costs	<b>B2b</b>	34	-	34	
Total support costs	<b>B2d</b>	16,499	-	16,499	
Total Governance costs	<b>B2e</b>	1,170	-	1,170	
<b>Total charitable expenditure</b>	<b>B2</b>	<b>90,800</b>	<b>56,211</b>	<b>147,011</b>	

### 29 Expenditure on raising funds and costs of investment management

<i>Current Year</i>		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2025 £	2025 £	2025 £	2024 £
Cost of fundraising activities		6,777	-	6,777	2,972
<b>Total fundraising costs</b>	<b>B1</b>	<b>6,777</b>	<b>-</b>	<b>6,777</b>	<b>2,972</b>

All the expenditure in the prior year was unrestricted.